Funding for this research was provided by:
Forskningsrådet i Sydöstra Sverige (FORSS-931904, FORSS-931904)
Accepted: 14 May 2022
First Online: 25 May 2022
: The study was reviewed and approved by the Swedish Ethical Review Authority (Dnr. 2020–00796).
: Not applicable.
: Andrea J Capusan has received speaker’s fees, and/or scientific advisory board compensation from Lundbeck, Indivior, Camurus, and DNE Pharma, all outside the scope of the current project.Björn Johnson has once received a speaker’s fee from Camurus outside the scope of current project.Olivia Liahaugen Flenburg has no competing interests to declare.